Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects.

Herman S, Niemelä V, Emami Khoonsari P, Sundblom J, Burman J, Landtblom AM, Spjuth O, Nyholm D, Kultima K.

Sci Rep. 2019 Mar 11;9(1):4129. doi: 10.1038/s41598-019-40186-5.

2.

Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.

Nielsen SM, Vinther-Jensen T, Nielsen JE, Nørremølle A, Hasholt L, Hjermind LE, Josefsen K.

J Neurol Sci. 2016 Mar 15;362:326-32. doi: 10.1016/j.jns.2016.02.018. Epub 2016 Feb 9.

PMID:
26944172
3.

A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease.

Vinther-Jensen T, Larsen IU, Hjermind LE, Budtz-Jørgensen E, Nielsen TT, Nørremølle A, Nielsen JE, Vogel A.

Orphanet J Rare Dis. 2014 Jul 17;9:114. doi: 10.1186/s13023-014-0114-8.

4.

Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.

Hart EP, Dumas EM, Giltay EJ, Middelkoop HA, Roos RA.

J Huntingtons Dis. 2013;2(2):137-47. doi: 10.3233/JHD-130059.

PMID:
25063511
5.

Basal ganglia-cortical structural connectivity in Huntington's disease.

Novak MJ, Seunarine KK, Gibbard CR, McColgan P, Draganski B, Friston K, Clark CA, Tabrizi SJ.

Hum Brain Mapp. 2015 May;36(5):1728-40. doi: 10.1002/hbm.22733. Epub 2015 Jan 30.

PMID:
25640796
6.

Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.

Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC, Palermo G, Czech C, Schobel S, Scahill RI, Heslegrave A, Zetterberg H, Wild EJ.

Sci Transl Med. 2018 Sep 12;10(458). pii: eaat7108. doi: 10.1126/scitranslmed.aat7108.

PMID:
30209243
7.

Molecular Imaging Markers to Track Huntington's Disease Pathology.

Wilson H, De Micco R, Niccolini F, Politis M.

Front Neurol. 2017 Jan 30;8:11. doi: 10.3389/fneur.2017.00011. eCollection 2017. Review.

8.

Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype.

Misiura MB, Lourens S, Calhoun VD, Long J, Bockholt J, Johnson H, Zhang Y, Paulsen JS, Turner JA, Liu J, Kara B, Fall E; PREDICT-HD Investigators & Working Group.

J Int Neuropsychol Soc. 2017 Feb;23(2):159-170. doi: 10.1017/S1355617716001132.

9.

Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.

Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP, Ringelstein EB, Lange HW.

Mov Disord. 2010 Oct 15;25(13):2195-202. doi: 10.1002/mds.23243.

PMID:
20645403
10.

Regional subcortical shape analysis in premanifest Huntington's disease.

Tang X, Ross CA, Johnson H, Paulsen JS, Younes L, Albin RL, Ratnanather JT, Miller MI.

Hum Brain Mapp. 2019 Apr 1;40(5):1419-1433. doi: 10.1002/hbm.24456. Epub 2018 Oct 30.

PMID:
30376191
11.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642124
12.

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators.

Lancet Neurol. 2011 Jan;10(1):31-42. doi: 10.1016/S1474-4422(10)70276-3. Epub 2010 Dec 2.

PMID:
21130037
13.

A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, Matson W, Hersch SM.

Ann Clin Transl Neurol. 2015 Jul;2(7):756-68. doi: 10.1002/acn3.214. Epub 2015 May 28.

14.
15.

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.

Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A.

J Clin Invest. 2015 May;125(5):1979-86. doi: 10.1172/JCI80743. Epub 2015 Apr 6.

16.

Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington's Disease.

Corey-Bloom J, Gluhm S, Herndon A, Haque AS, Park S, Gilbert PE.

J Huntingtons Dis. 2016;5(1):91-6. doi: 10.3233/JHD-150175.

PMID:
27003664
17.

Molecular Imaging in Huntington's Disease.

Wilson H, Politis M.

Int Rev Neurobiol. 2018;142:289-333. doi: 10.1016/bs.irn.2018.08.007. Epub 2018 Aug 29.

PMID:
30409256
18.

Visual Object Perception in Premanifest and Early Manifest Huntington's Disease.

Coppen EM, Jacobs M, van der Zwaan KF, Middelkoop HAM, Roos RAC.

Arch Clin Neuropsychol. 2019 Feb 23. pii: acz002. doi: 10.1093/arclin/acz002. [Epub ahead of print]

PMID:
30796801
19.

Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington's disease gene-expansion carriers.

Unmack Larsen I, Vinther-Jensen T, Gade A, Nielsen JE, Vogel A.

J Int Neuropsychol Soc. 2015 Mar;21(3):193-202. doi: 10.1017/S1355617715000090. Epub 2015 Apr 8.

PMID:
25850430
20.

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.

Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

Supplemental Content

Support Center